Former United States Securities and Exchange Commission attorney Willie
Briscoe, founder of The
Briscoe Law Firm, PLLC, and the securities litigation firm of Powers
Taylor, LLP announce that the firms are investigating legal claims
against the officers and Board of ViroPharma
Incorporated (“ViroPharma”) (NASDAQ: VPHM) related to potential
securities violations by ViroPharma between December 14, 2011 and April
9, 2012 (the “Class Period”).
If you are an affected investor and you want to learn more about the
lawsuit or join the action, contact Patrick Powers at Powers Taylor,
LLP, toll free (877) 728-9607, via e-mail at email@example.com,
or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via
email at WBriscoe@TheBriscoeLawFirm.com.
There is no cost or fee to you.
In a recently filed class action lawsuit, ViroPharma and certain of its
officers and directors were charged with violating certain provisions of
the Securities Exchange Act of 1934. Notably, the complaint alleges that
defendants’ misrepresented and/or failed to disclose that (1) ViroPharma
had no basis for its stated belief that a new supplemental drug
application ("sNDA") approval for Vancocin would qualify for three
additional years of exclusivity; and (2) generic Vancomycin capsules
would not be approved during that time. However, on April 10, 2012,
ViroPharma announced that the sNDA approval would not qualify for three
additional years of exclusivity, and that the FDA indicated that it was
approving three applications for generic Vancomycin capsules. As a
result of the announcement, ViroPharma shares dropped by 22%.
Briscoe Law Firm, PLLC is a full service business litigation,
commercial transaction, and public advocacy firm with more than 20 years
of experience in complex litigation and transactional matters.
Taylor, LLP is a boutique litigation law firm that handles a variety
of complex business litigation matters, including claims of investor and
stockholder fraud, shareholder oppression, shareholder derivative suits,
and security class actions.